Literature DB >> 20100969

Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons.

Andy I Choi1, Yongmei Li, Steven G Deeks, Carl Grunfeld, Paul A Volberding, Michael G Shlipak.   

Abstract

BACKGROUND: Cardiovascular disease (CVD) is now a leading cause of death in HIV-infected persons; however, risk markers for CVD are ill defined in this population. We examined the association between longitudinal measures of kidney function and albuminuria with risk of atherosclerotic CVD and heart failure in a contemporary cohort of HIV-infected individuals. METHODS AND
RESULTS: We followed a national sample of 17 264 HIV-infected persons receiving care in the Veterans Health Administration for (1) incident CVD, defined as coronary, cerebrovascular, or peripheral arterial disease, and (2) incident heart failure. Rates of CVD and heart failure were at least 6-fold greater in the highest-risk patients with an estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m(2) and albuminuria > or =300 mg/dL versus those with no evidence of kidney disease (eGFR > or =60 mL/min per 1.73 m(2) and no albuminuria). After multivariable adjustment, eGFR levels 45 to 59, 30 to 44, and <30 mL/min per 1.73 m(2) were associated with hazard ratios for incident CVD of 1.46 (95% confidence interval, 1.15 to 1.86), 2.03 (1.47 to 2.82), and 1.99 (1.46 to 2.70) compared with eGFR > or =60 mL/min per 1.73 m(2). Similarly, albuminuria levels 30, 100, and > or =300 mg/dL had hazard ratios for CVD of 1.28 (1.09 to 1.51), 1.48 (1.15 to 1.90), and 1.71 (1.30 to 2.27) compared with absent albuminuria. The associations between eGFR and albuminuria with heart failure were larger in magnitude and followed the same trends.
CONCLUSIONS: In this national sample of HIV-infected persons, eGFR and albuminuria levels were strongly associated with risk of CVD and heart failure. Kidney function and albuminuria provide complementary prognostic information that may aid CVD risk stratification in HIV-infected persons.

Entities:  

Mesh:

Year:  2010        PMID: 20100969      PMCID: PMC2829672          DOI: 10.1161/CIRCULATIONAHA.109.898585

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  42 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

3.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

4.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-31       Impact factor: 29.690

5.  Data resources in the Department of Veterans Affairs.

Authors:  Charles Maynard; Michael K Chapko
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

6.  Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.

Authors:  Carl Grunfeld; Joseph A C Delaney; Christine Wanke; Judith S Currier; Rebecca Scherzer; Mary L Biggs; Phyllis C Tien; Michael G Shlipak; Stephen Sidney; Joseph F Polak; Daniel O'Leary; Peter Bacchetti; Richard A Kronmal
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

7.  Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Alba Phippard; David Cohen; Daniel O Scharfstein; Thomas A Louis
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

8.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

9.  Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.

Authors:  Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Paul A Volberding; Diane Havlir; Daniel Bertenthal; Alan Bostrom; Ann M O'Hare
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  82 in total

1.  Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

Authors:  Andy I Choi; Eric Vittinghoff; Steven G Deeks; Cristin C Weekley; Yongmei Li; Michael G Shlipak
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

2.  Preventing Heart Failure in Inflammatory and Immune Disorders.

Authors:  Maya Serhal; Chris T Longenecker
Journal:  Curr Cardiovasc Risk Rep       Date:  2014-06

3.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

4.  Associations of Urine Biomarkers with Kidney Function Decline in HIV-Infected and Uninfected Men.

Authors:  Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Michael G Shlipak; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael R Bennett; Chirag R Parikh; Joachim H Ix; Vasantha Jotwani
Journal:  Am J Nephrol       Date:  2019-09-25       Impact factor: 3.754

5.  Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.

Authors:  Samir K Gupta; Changyu Shen; Kieren J Mather; Rajiv Agarwal; Michael P Dubé
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

6.  Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.

Authors:  S Leone; M Prosperi; S Costarelli; P Nasta; F Maggiolo; S Di Giambenedetto; A Saracino; M Di Pietro; A Gori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-06       Impact factor: 3.267

Review 7.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 8.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

9.  Kidney Transplantation in HIV-Infected Recipients: Encouraging Outcomes, but Registry Data Are No Longer Enough.

Authors:  Alissa J Wright; John S Gill
Journal:  J Am Soc Nephrol       Date:  2015-03-19       Impact factor: 10.121

10.  Recurrent HIV-associated immune complex glomerulonephritis with lupus-like features after kidney transplantation.

Authors:  Sindhu Chandran; Kuang-Yu Jen; Zoltan G Laszik
Journal:  Am J Kidney Dis       Date:  2013-03-05       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.